OTHER FUNCTIONS R&D- BIOMEDICAL (BASIC RESEARCH)

显然需要更好地定义患者特异性治疗策略，以使用标准和新型治疗方法来治疗急性髓性白血病（AML），以提高疗效并减少不必要的副作用。Eutropics Pharmaceuticals通过使用一种专有的检测方法，提供一种新的预测性生物标志物BH3分析，在提高AML治疗效果方面处于独特的地位。该分析独特地评估了癌细胞中的线粒体功能。该技术已在患者测试集中得到验证，可预测患者对AML标准治疗的反应。

There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and reduce unnecessary side effects. Eutropics Pharmaceuticals is uniquely positioned to improve therapy efficacy for AML by using a proprietary assay that provides a novel predictive biomarker, BH3 profiling. The assay uniquely assesses mitochondrial functionality in cancer cells. This technology is proven in a patient test set to predict the patient responsiveness to standard treatments for AML. In this phase I contract Eutropics will deliver a refined standard operating protocol for a FACS based version of the BH3 profiling assay while seeking CLIA 88 approval. Biopsied AML patient samples will be obtained from several academic cancer centers under collaboration agreements that are in place and sent to Eutropics labs in Cambridge, MA. Data collected from the assay will be correlated with patient outcome data collected by physicians. Eutropics will apply for the phase 2 study that will deliver a clinically validated test for AML and companion diagnostic test for standard of care and experimental AML treatments. Discussions are underway for commercial collaborations.